Acutaas Chemicals Q4 FY26 Earnings Call Transcript Released
Acutaas Chemicals released its Q4 FY26 earnings call transcript. The company reported FY26 revenue of ₹1,339.4 crore (up 33% YoY) and PAT of ₹356.4 crore. Q4 FY26 revenue was ₹432.8 crore (up 40.3% YoY) with PAT at ₹134.3 crore. The company expects 25% revenue growth in FY27 and aims to maintain similar EBITDA margins.
The announcement details strong financial performance and future growth strategies across multiple business verticals, including new ventures like battery chemicals and semiconductors, which are key growth drivers for the company.
The company reported strong financial results with significant year-on-year growth in revenue and profit, and provided a positive outlook for the next fiscal year. The management also highlighted progress in strategic initiatives like battery chemicals and semiconductor businesses.
Acutaas Chemicals Limited (formerly Ami Organics Limited) has released the transcript of its earnings conference call held on April 30, 2026, to discuss the financial results for the fourth quarter and the full year ended March 31, 2026. The company reported a strong financial performance for FY26, with revenue from operations reaching ₹1,339.4 crores, a 33% increase year-on-year. The Profit After Tax (PAT) for FY26 stood at ₹356.4 crores, more than doubling compared to the previous year. For the fourth quarter of FY26, revenue from operations was ₹432.8 crores, a 40.3% year-on-year growth, with PAT at ₹134.3 crores, up 114.1% year-on-year. EBITDA margins for the quarter were a robust 42.4%.
The management discussed significant progress in strategic initiatives, including the battery chemical business with two products commercialized and two more expected in FY27. The semiconductor business is also showing traction, with new products expected to contribute meaningfully. The South Korea joint venture, Indichem, has its R&D center operational, and samples are being sent to prospective customers. The company is confident in its multi-vertical strategy, anticipating battery chemicals and semiconductors to become self-sustaining growth engines by FY28.
Acutaas Chemicals has guided for a 25% revenue growth in FY27, maintaining EBITDA margins at similar levels to FY26, driven by a product portfolio upgrade and improving business mix. The company is also expanding its R&D center with a planned 10x capacity expansion to support innovation across various sectors.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.